June 17, 2014

Teva has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to a patent for Teva’s wakefulness product, Nuvigil (armodafinil) tablets.

June 13, 2014

Teva Pharmaceutical Industries on Thursday announced that the U.S. Court of Appeals for the Federal Circuit upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb's entecavir compound claim of U.S. Patent No. 5,206,244 invalid.

June 9, 2014

Teva on Monday announced that the Food and Drug Administration approved an expanded label for Azilect (rasagiline tablets) from monotherapy and adjunct to levodopa to now include dopamine agonists.

June 3, 2014

Teva Pharmaceutical and Labrys Biologics, a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, on Tuesday announced that Teva has entered into a definitive agreement to acquire Labrys in a deal for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch milestones.

June 2, 2014

Teva Pharmaceutical Industries on Monday announced a new organizational structure and executive positions. The changes, which will become effective July 1, are designed to improve global integration and effectiveness across the company, Teva said.

May 30, 2014

Teva Pharmaceutical Industries announced on Friday that the U.S. District Court for the Northern District of West Virginia has denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex (celecoxib) 100-, 200- and 400-mg capsules.

May 23, 2014

Teva Pharmaceutical on Friday announced that the Food and Drug Administration approved the use of QVAR (beclomethasone dipropionate HFA) with a dose counter for the treatment of asthma in patients 5 years of age and older.

May 13, 2014

Teva Pharmaeceuticals on Tuesday announced that the Food and Drug Administration accepted the company's supplemental new drug application for a lower dose QNASL (beclomethasone dipropionate) nasal aerosol, which is used for the treatment of seasonal and perennial allergic rhinitis in children ages 4 years to 11 years.

May 6, 2014

Teva Pharmaceutical Industries last week announced results for first quarter 2014 ended March 31.

May 5, 2014

Teva Pharmaceutical Industries on Monday announced that the Food and Drug Administration approved Synribo (omacetaxine mepesuccinate) for injection, to include home administration.

April 17, 2014

Teva Pharmaceutical announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.

April 15, 2014

Teva Pharmaceutical Industries announced the launch of a generic equivalent to Lunesta (eszopiclone tablets) in 1-,2- and 3-mg form in the United States.

April 8, 2014

Teva Pharmaceutical Industries announced that it has received approval from the Food and Drug Administration for its generic form of Lovaza (omega-3-acid ethyl esters capsules, USP) in the United States.

April 1, 2014

Teva Pharmaceuticals on Tuesday announced the introduction and availability of Raloxifene hydrochloride tablets, USP.

March 7, 2014

Teva Pharmaceutical Industries will launch the generic version of Xeloda (capecitabine) tablets, 150 mg and 500 mg, in the United States.

March 4, 2014

Teva Pharmaceutical Industries announced that it received approval for generic Evista (raloxifene) tablets, 60-mg, in the United States.

March 3, 2014

Teva Pharmaceutical Industries announced the launch of Adasuve (loxapine) inhalation powder in a 10-mg dosage. The drug is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.

February 13, 2014

Teva Pharmaceutical Industries announced that the Food and Drug Administration has granted full approval of Synribo (omacetaxine mepesuccinate) for injection.

January 29, 2014

Teva announced that the Food and Drug Administration approved its supplemental new drug application for three-times-a-week Copaxone in 40mg/mL form.

January 21, 2014

Teva Pharmaceutical announced that it has entered into a definitive agreement under which Teva will acquire NuPathe for $3.65 per share in cash.

January 9, 2014

Teva Pharmaceutical Industries has appointed Erez Vigodman as president and CEO, the Israeli drug maker said Thursday.

January 3, 2014

Teva Pharmaceutical Industries has launched an authorized generic version of a drug used to treat overactive bladder, the company said Friday.

December 10, 2013

Teva Pharmaceutical Industries anticipates that it could lose about $500 million in sales next year if a generic version of its multiple sclerosis drug hits the market, the Israeli drug maker said Tuesday.

December 2, 2013

The Food and Drug Administration has designated a drug made by Teva Pharmaceutical Industries as an orphan drug, the company said.